Disitamab + ENVAFOLIMAB for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Sep 2024: Trial started, NCT06663007
  2. 29 Oct 2024: Trial registered, NCT06663007

The trials

NCT06663007: RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

State
Under way
Phase
Phase 1 and Phase 2
People
72 planned
Started
24 Sep 2024
Primary completion
31 May 2027
Arms
Cohort A
Results
None posted
  1. 24 Sep 2024: Trial started
  2. 29 Oct 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.